Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Overview of attention for article published in Frontiers in oncology, August 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 2 news outlets

twitter: 2 X users

Citations

dimensions_citation: 34 Dimensions

Readers on

mendeley: 50 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 34 publications that cite this research output.

34

The most recent citing publications are shown below. View all 34 publications that cite this research output on Dimensions.

A comprehensive clinical evaluation of HER2-TKIs in patients with previously treated HER2-positive metastatic breast cancer

Article in Anti-Cancer Drugs (April 2024)

Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in China

Preprint in Research Square (February 2024)

Cost-effectiveness of Metronomic chemotherapy vs Weekly Intravenous Paclitaxel in patients with ER+/HER2-Metastatic Breast Cancer

Preprint in Research Square (January 2024)